首页> 美国卫生研究院文献>Journal of Lipid Research >Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice
【2h】

Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice

机译:从小鼠循环中快速清除溶血磷脂酸和相关脂质的机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lysophosphatidic acid (LPA) is a bioactive lipid mediator. Concentrations of the major LPA species in mouse plasma decreased uniformly following administration of a potent selective inhibitor of the LPA-generating lysophospholipase D autotaxin, identifying an active mechanism for removal of LPA from the circulation. LPA, akylglycerol phosphate (AGP), sphingosine 1-phosphate (S1P), and a variety of structural mimetics of these lipids, including phosphatase-resistant phosphonate analogs of LPA, were rapidly eliminated (t1/2 < 30 s) from the circulation of mice following intravenous administration of a single bolus dose without significant metabolism in situ in the blood. These lipids accumulated in the liver. Elimination of intravenously administered LPA was blunted by ligation of the hepatic circulation, and ∼90% of LPA administered through the portal vein was accumulated by the isolated perfused mouse liver at first pass. At early times following intravenous administration, more LPA was associated with a nonparenchymal liver cell fraction than with hepatocytes. Primary cultures of nonparenchymal liver cells rapidly assimilated exogenously provided LPA. Our results identify hepatic uptake as an important determinant of the bioavailability of LPA and bioactive lysophospholipid mimetics and suggest a mechanism to explain changes in circulating LPA levels that have been associated with liver dysfunction in humans.
机译:溶血磷脂酸(LPA)是一种生物活性脂质介体。施用有效的产生LPA的溶血磷脂酶D自分泌紫杉醇的选择性抑制剂后,小鼠血浆中主要LPA种类的浓度均匀下降,这确定了从循环中去除LPA的有效机制。 LPA,磷酸烷基甘油酯(AGP),1-磷酸鞘氨醇(S1P)以及这些脂质的各种结构模拟物(包括LPA的耐磷酸酶的膦酸酯类似物)被迅速消除(t1 / 2 <30 s)。在静脉内给予单次推注剂量后,小鼠血液中没有明显的新陈代谢。这些脂质在肝脏中积累。结扎肝循环使静脉注射LPA的消除减弱,并且通过门静脉注射的LPA的约90%在第一遍被分离的灌注小鼠肝脏蓄积。在静脉内给药后的早期,与肝实质相比,更多的LPA与非实质肝细胞组分相关。非实质肝细胞的原代培养物迅速地被外源吸收,提供了LPA。我们的研究结果表明,肝脏吸收是LPA和生物活性溶血磷脂模拟物生物利用度的重要决定因素,并提出了一种机制来解释循环LPA水平的变化,该水平与人的肝功能障碍有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号